Neutrophil-to-lymphocyte ratio predicts early mortality in females with metastatic triple-negative breast cancer

Gabriel de la Cruz-Ku, Diego Chambergo-Michilot, J. Smith Torres-Roman, Pamela Rebaza, Joseph Pinto, Jhajaira Araujo, Zaida Morante, Daniel Enriquez, Claudio Flores, Renato Luque, Antonella Saavedra, Maria Lujan, Henry Gomez, Bryan Valcarcel

Producción científica: Contribución a una revistaArtículorevisión exhaustiva

7 Citas (Scopus)

Resumen

Background The aim of this study was to determine the utility of the neutrophil-to-lymphocyte ratio (NLR) as a biomarker for predicting early-mortality (<2 years) among females with metastatic triple-negative breast cancer (mTNBC). Methods We reviewed 118 medical records of females with mTNBC. The cut-off value for the NLR (<2.5 and ≥2.5) was determined with receiver operating characteristic curves (area under the curve: 0.73; 95% CI: 0.62–0.85). Survival curves were estimated using the Kaplan-Meier method and compared with the Log-rank test. Multivariate Cox regression was used to identify the risk of mortality at two years. Moreover, we performed sensitivity analyses with different cut-off values and a subgroup analysis in females that only received chemotherapy. Results The median follow-up was 24 months. Females with NLR ≥2.5 had a poor overall survival compared to females with NLR <2.5 (6% vs. 28%, p<0.001) at two years. This outcome remained when we stratified for females that only received chemotherapy (8% vs. 36%, p = 0.001). Multivariate analyses identified NLR ≥2.5 as a poor prognostic risk factor for mortality in the entire population (HR: 2.12, 95% CI: 1.32–3.39) and among females that received chemotherapy (HR: 2.68, 95% CI: 1.46–4.92). Conclusion The NLR is an accessible and reliable biomarker that predicts early mortality among females with mTNBC. Our results suggest that females with high NLR values have poor prognosis despite receiving standard chemotherapy. Health providers should evaluate the possibility to enroll these patients in novel immunotherapy trials.

Idioma originalInglés
Número de artículoe0243447
PublicaciónPLoS ONE
Volumen15
N.º12 December
DOI
EstadoPublicada - dic. 2020

Huella

Profundice en los temas de investigación de 'Neutrophil-to-lymphocyte ratio predicts early mortality in females with metastatic triple-negative breast cancer'. En conjunto forman una huella única.

Citar esto